Pfs25-EPA/Alhydrogel

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Malaria

Phase 1

Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)

CompletedNCT01434381

National Institute of Allergy and Infectious Diseases (NIAID)Malaria

Start: 2011-08-31End: 2013-08-31Updated: 2014-02-11

Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine

CompletedNCT01867463

National Institute of Allergy and Infectious Diseases (NIAID)Malaria

Start: 2013-03-27End: 2016-12-19Updated: 2018-07-05

Related Papers

Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.

2018-07-2782 citations

Utilizing direct skin feeding assays for development of vaccines that interrupt malaria transmission: A systematic review of methods and case study.

2016-10-2411 citations